These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7922982)

  • 21. Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients.
    Bleul C; Müller M; Frank R; Gausepohl H; Koldovsky U; Mgaya HN; Luande J; Pawlita M; ter Meulen J; Viscidi R
    J Clin Microbiol; 1991 Aug; 29(8):1579-88. PubMed ID: 1722219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epitope mapping of the human papillomavirus type 16 E4 protein by means of synthetic peptides.
    Suchánková A; Krchnák V; Vágner J; Hamsíková E; Krcmár M; Ritterová L; Vonka V
    J Gen Virol; 1992 Feb; 73 ( Pt 2)():429-32. PubMed ID: 1371544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus-related serological markers of invasive cervical carcinoma in Brazil.
    Sun Y; Eluf-Neto J; Bosch FX; Muñoz N; Booth M; Walboomers JM; Shah KV; Viscidi RP
    Cancer Epidemiol Biomarkers Prev; 1994 Jun; 3(4):341-7. PubMed ID: 8061584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women.
    Ramezani A; Aghakhani A; Soleymani S; Bavand A; Bolhassani A
    BMC Infect Dis; 2019 Feb; 19(1):142. PubMed ID: 30755156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of serum antibodies to HPV-16 L1 virus-like particles in patients with invasive cervical cancer.
    Skiba D; Mehlhorn G; Fasching PA; Beckmann MW; Ackermann S
    Anticancer Res; 2006; 26(6C):4921-6. PubMed ID: 17214363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study.
    Lei J; Ploner A; Lagheden C; Eklund C; Nordqvist Kleppe S; Andrae B; Elfström KM; Dillner J; Sparén P; Sundström K
    PLoS Med; 2018 Oct; 15(10):e1002666. PubMed ID: 30273338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High prevalence of serum antibodies to Ras and type 16 E4 proteins of human papillomavirus in patients with precancerous lesions of the uterine cervix.
    Pedroza-Saavedra A; Cruz A; Esquivel F; De La Torre F; Berumen J; Gariglio P; Gutiérrez L
    Arch Virol; 2000; 145(3):603-23. PubMed ID: 10795526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The E7 protein of human papillomavirus (HPV) type 16 expressed by recombinant vaccinia virus can be used for detection of antibodies in sera from cervical cancer patients.
    Nindl I; Gissmann L; Fisher SG; Bribiesca LB; Berumen J; Müller M
    J Virol Methods; 1996 Oct; 62(1):81-5. PubMed ID: 8910651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Humoral immune response against proteins E6 and E7 in cervical carcinoma patients positive for human papilloma virus type 16 during treatment and follow-up.
    Baay MF; Duk JM; Burger MP; de Bruijn HW; Stolz E; Herbrink P
    Eur J Clin Microbiol Infect Dis; 1999 Feb; 18(2):126-32. PubMed ID: 10219577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer.
    Burger RA; Monk BJ; Kurosaki T; Anton-Culver H; Vasilev SA; Berman ML; Wilczynski SP
    J Natl Cancer Inst; 1996 Oct; 88(19):1361-8. PubMed ID: 8827013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals.
    Luxton JC; Rowe AJ; Cridland JC; Coletart T; Wilson P; Shepherd PS
    J Gen Virol; 1996 Jul; 77 ( Pt 7)():1585-93. PubMed ID: 8758003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer.
    Bonfrer JM; Gaarenstroom KN; Kenter GG; Korse CM; Hart AA; Gallee MP; Helmerhorst TJ; Kenemans P
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):371-5. PubMed ID: 7530676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA.
    Krchnák V; Vágner J; Suchánková A; Krcmár M; Ritterová L; Vonka V
    J Gen Virol; 1990 Nov; 71 ( Pt 11)():2719-24. PubMed ID: 2174961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of seroreactive epitopes of human papillomavirus type 18 E7 protein by synthetic peptides.
    Krchnák V; Pistĕk T; Vágner J; Suchánková A; Kañka J; Ritterová L; Vonka V
    Acta Virol; 1993 Oct; 37(5):395-402. PubMed ID: 7514354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients.
    de Boer MA; Jordanova ES; Kenter GG; Peters AA; Corver WE; Trimbos JB; Fleuren GJ
    Clin Cancer Res; 2007 Jan; 13(1):132-8. PubMed ID: 17200347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective study on cervical neoplasia IV. Presence of HPV antibodies.
    Vonka V; Hamsíková E; Kanka J; Ludvíková V; Sapp M; Smahel M
    Int J Cancer; 1999 Jan; 80(3):365-8. PubMed ID: 9935175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of antibodies against human papillomavirus type 16 E4 and E7 proteins in sera of patients with cervical neoplasias.
    Stoian M; Repanovici R
    Rev Roum Virol; 1994; 45(3-4):185-92. PubMed ID: 7619739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls.
    Hamsiková E; Novák J; Hofmannová V; Munoz N; Bosch FX; de Sanjosé S; Shah K; Roth Z; Vonka V
    J Infect Dis; 1994 Dec; 170(6):1424-31. PubMed ID: 7995981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of ELISA and western blotting for human papillomavirus type 16 E7 antibody determination.
    Suchánková A; Ritterová L; Krcmár M; Krchnák V; Vágner J; Jochmus I; Gissmann L; Kanka J; Vonka V
    J Gen Virol; 1991 Oct; 72 ( Pt 10)():2577-81. PubMed ID: 1655964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma.
    Ressler S; Scheiden R; Dreier K; Laich A; Müller-Holzner E; Pircher H; Morandell D; Stein I; Viertler HP; Santer FR; Widschwendter A; Even J; Jansen-Dürr P; Capesius C; Zwerschke W
    Clin Cancer Res; 2007 Dec; 13(23):7067-72. PubMed ID: 18056184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.